Neogen Corporation updated earnings guidance for its full-year 2025. For the year, the company now expected its revenue to be in the range of $905 million to $925 million. Primarily due to the strengthening of the U.S. dollar and, to a lesser degree, a delay in the ramp-up of sample collection production and the voluntary attrition of genomics revenue related to restructuring activities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.37 USD | -2.81% |
|
-9.51% | -14.58% |
01-21 | Neogen Introduces Igenity BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Risk | CI |
01-16 | Neogen® Launches New MDA2 Quantitative Salmonella Molecular Detection Assay | CI |
Stocks mentioned in the article
Price |
Change |
5d. change |
Capi. | ||
---|---|---|---|---|---|
10.37USD | -2.81% | -9.51% | 2.25B | ||
1.0327USD | 0.00% | +0.78% | - | ||
0.0114USD | -0.04% | -1.72% | - | ||

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NEOG Stock
- News Neogen Corporation
- Neogen Corporation Updates Earnings Guidance for Its Full-Year 2025